G43 

G43 is a potent, selective glucosyltransferase inhibitor, with the K_d of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to S. mutans in vitro and in vivo, and can be used for dental caries study^[1][2].

G43 (16 h) inhibits more than 85% of S. mutans biofilm at 12.5 μM^[1].
G43 (25 μM, 24 h) reduces the glucan production by the glucosyltransferase (Gtfs), and consistently inhibits the activity of both GtfB and GtfC with 80% inhibition of both enzymes^[1].
G43 (up to 25 μM, 24 h) shows no significant difference on expression of gtfs (gtfB, gtfC and gtfD) in S. mutans. UA159 cells^[1].
G43 (50 μM, 24-48 h) reduces the biofilm formation by decreasing the production of Water-insoluble extracellular polysaccharide in wild-type S. mutans^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

G43 (100 µM twice daily for 4 weeks, topically administration) reduces S. mutans virulence in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

341.34

C₁₆H₁₁N₃O₄S

690693-02-8

O=C(C1=CC2=C(S1)C=CC([N+]([O-])=O)=C2)NC3=CC=CC=C3C(N)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang Q, et al. Structure-Based Discovery of Small Molecule Inhibitors of Cariogenic Virulence. Sci Rep. 2017;7(1):5974.  [Content Brief]

  [2]. Scaffa PMC, et al. The potential use of glycosyl-transferase inhibitors for targeted reduction of S. mutans biofilms in dental materials. Sci Rep. 2023;13(1):11889.  [Content Brief]